Answers are grounded in this paper and cite their sources.
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for hematologic malignancies, and outcomes have improved over time [ 1 ]. However, Hispanic and non-Hispanic Black (NHB) patients have worse overall survival (OS) compared to non-Hispanic White (NHW) patients and are less likely to utilize an unrelated HCT donor [ 2 , 3 ], but this difference has not been evaluated in the post-transplant cyclophosphamide (PTCy) era. PTCy reduces GvHD and allows for increased availability of alternative allogeneic donors in minority patients [ 4 ].
No takes yet. Share an insight, caveat, or question.
Herr et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: